Summit Partners Public Asset Management, LLC Verona Pharma PLC Transaction History
Summit Partners Public Asset Management, LLC
- $3.79 Billion
- Q3 2025
A detailed history of Summit Partners Public Asset Management, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Summit Partners Public Asset Management, LLC holds 1,785,407 shares of VRNA stock, worth $191 Million. This represents 5.03% of its overall portfolio holdings.
Number of Shares
1,785,407
Previous 2,144,286
16.74%
Holding current value
$191 Million
Previous $203 Million
6.08%
% of portfolio
5.03%
Previous 6.35%
Shares
4 transactions
Others Institutions Holding VRNA
# of Institutions
246Shares Held
78.5MCall Options Held
686KPut Options Held
442K-
Pentwater Capital Management LP Naples, FL5.3MShares$567 Million3.55% of portfolio
-
Ubs Oconnor LLC Chicago, IL4.28MShares$458 Million27.57% of portfolio
-
Hbk Investments L P Dallas, TX4.26MShares$456 Million6.29% of portfolio
-
Fil LTD Hamilton, D03.49MShares$373 Million0.32% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million15.27% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...